Skip to main content
Premium Trial:

Request an Annual Quote

Ingenuity Extends Pathway Analysis Software Deal With Merck

NEW YORK (GenomeWeb News) — Ingenuity Systems today said it has extended a licensing agreement with Merck that allows the drug maker to continue using its Ingenuity Pathways Analysis Software.
 
Under the terms of the “multi-year” agreement, Merck will continue to use the IPA software for research in “multiple therapeutic areas,” Ingenuity said.
 
The original agreement was signed in 2004, but the company did not say when the extended licensing contract will expire.
 
Ingenuity said the software supports biomarker target identification and validation, predictive toxicology, and pharmacogenomics on “all high throughput analysis platforms.”
 
Financial terms of the agreement were not released.

Filed under

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.